Bristol licenses non-Rx drugs to Reckitt Benckiser for $482M

02/14/2013 | PharmaTimes (U.K.)

Reckitt Benckiser is paying $482 million for rights to market some of Bristol-Myers Squibb's nonprescription medications in Latin America. The three-year deal includes the painkiller Tempra, the antacid Picot, and cough and cold drug Naldecon. After three years, Reckitt Benckiser will be given the option to acquire legal rights and intellectual property for the treatments.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC